Status:
COMPLETED
Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Lead Sponsor:
AstraZeneca
Conditions:
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with c...
Detailed Description
An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cance...
Eligibility Criteria
Inclusion
- Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV). Mixed histology of small cell and non-small cell lung cancer
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
4243 Patients enrolled
Trial Details
Trial ID
NCT00997230
Start Date
September 1 2009
End Date
October 1 2012
Last Update
October 28 2013
Active Locations (118)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aachen, Germany
2
Research Site
Amberg, Germany
3
Research Site
Ansbach, Germany
4
Research Site
Aschaffenburg, Germany